Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Jenner

Showing results (131-140 of 177) with videos related to

Pageof 18
Sort By:
Expert Review of Neurotherapeutics|August 7, 2020
'Dopamine agonist Phobia' in Parkinson's disease: when does it matter? Implications for non-motor symptoms and personalized medicineSilvia Rota, Iro Boura, Lucia Batzu, et al.
Neuroreport|August 9, 2002
Proteasome inhibition causes nigral degeneration with inclusion bodies in ratsKevin St P McNaught, Lars M Björklund, Roger Belizaire, et al.
The Journal of Biological Chemistry|May 30, 2002
Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasomeDong-Hoon Hyun, MoonHee Lee, Nobutaka Hattori, et al.
The European Journal of Neuroscience|July 28, 2005
The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activationMahmoud M Iravani, Clement C M Leung, Mona Sadeghian, et al.
Behavioural Pharmacology|March 14, 2007
Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primatesSarah Rose, Dieter K A Scheller, Alexander Breidenbach, et al.
European Journal of Pharmacology|September 30, 2015
The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosetsShin-ichi Uchida, Kazuhiro Soshiroda, Eri Okita, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 3, 2002
The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosetsRonald K B Pearce, Lance A Smith, Michael J Jackson, et al.
Sleep Medicine|September 10, 2014
Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease)Christopher J Earley, James Connor, Diego Garcia-Borreguero, et al.
Pharmacology, Biochemistry, and Behavior|December 8, 2004
Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosetsMichael J Jackson, Ghassan Al-Barghouthy, Ronald K B Pearce, et al.
CNS Drugs|February 9, 2021
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical ExperienceVanessa Raeder, Iro Boura, Valentina Leta, et al.
Pageof 18

Showing results (131-140 of 177) with videos related to

Sort By:
Pageof 18
Expert Review of Neurotherapeutics|August 7, 2020
'Dopamine agonist Phobia' in Parkinson's disease: when does it matter? Implications for non-motor symptoms and personalized medicineSilvia Rota, Iro Boura, Lucia Batzu, et al.
Neuroreport|August 9, 2002
Proteasome inhibition causes nigral degeneration with inclusion bodies in ratsKevin St P McNaught, Lars M Björklund, Roger Belizaire, et al.
The Journal of Biological Chemistry|May 30, 2002
Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasomeDong-Hoon Hyun, MoonHee Lee, Nobutaka Hattori, et al.
The European Journal of Neuroscience|July 28, 2005
The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activationMahmoud M Iravani, Clement C M Leung, Mona Sadeghian, et al.
Behavioural Pharmacology|March 14, 2007
Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primatesSarah Rose, Dieter K A Scheller, Alexander Breidenbach, et al.
European Journal of Pharmacology|September 30, 2015
The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosetsShin-ichi Uchida, Kazuhiro Soshiroda, Eri Okita, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 3, 2002
The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosetsRonald K B Pearce, Lance A Smith, Michael J Jackson, et al.
Sleep Medicine|September 10, 2014
Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease)Christopher J Earley, James Connor, Diego Garcia-Borreguero, et al.
Pharmacology, Biochemistry, and Behavior|December 8, 2004
Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosetsMichael J Jackson, Ghassan Al-Barghouthy, Ronald K B Pearce, et al.
CNS Drugs|February 9, 2021
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical ExperienceVanessa Raeder, Iro Boura, Valentina Leta, et al.
Pageof 18